IGC Pharma Reports Second Quarter Fiscal 2024 Results
IGC-ADI addressing agitation in dementia due to Alzheimer’s progresses in Phase 2 Trial Company focuses on advancing the development of an expanded IP portfolio targeting Alzheimer’s POTOMAC, Md.–(BUSINESS WIRE)–#AD–IGC Pharma,…
Details